Look at Celgene, Otezla is now a blockbuster with over $1B in 2016. It was only launched in late 2014 so basically it took 2 years to become a blockbuster. Amgen's Kyprolis and PCSK9s could only dream of such success.
http://files.shareholder.com/downlo...3A7C2/CELG_News_2017_1_9_General_Releases.pdf
Total net product sales are expected to be approximately $11,187 million, up 22 percent year-over year.
Celgene Expects Strong Product Sales and Earnings Growth in 2017 Year-over-Year Change*
Total Revenue Approximately $13.0B to $13.4B
Otzela at the low end will be a $1.5B drug or 2X Kyprolis sales and like 3X Enbrel derm sales!
Revlimid and Pomalyst combined revenue in MM is the cost of Amgen's $10B Onyx acquisition. Amgen BD does rightfully suck, but Amgen reps could sell HIV drugs to dying AIDS patients.
http://files.shareholder.com/downlo...3A7C2/CELG_News_2017_1_9_General_Releases.pdf
Total net product sales are expected to be approximately $11,187 million, up 22 percent year-over year.
- REVLIMID®: $6,976 million, 20 percent year-over-year increase
- POMALYST®/IMNOVID®: $1,311 million, 33 percent year-over-year increase
- OTEZLA®: $1,017 million, 116 percent year-over-year increase
- ABRAXANE®: $973 million, 1 percent year-over-year increase
Celgene Expects Strong Product Sales and Earnings Growth in 2017 Year-over-Year Change*
Total Revenue Approximately $13.0B to $13.4B
- REVLIMID® Net Sales Approximately $8.0B to $8.3B
- POMALYST®/ IMNOVID® Net Sales Approximately $1.6B
- OTEZLA® Net Sales Approximately $1.5B to $1.7B
- ABRAXANE® Net Sales Approximately $1.0B
Otzela at the low end will be a $1.5B drug or 2X Kyprolis sales and like 3X Enbrel derm sales!
Revlimid and Pomalyst combined revenue in MM is the cost of Amgen's $10B Onyx acquisition. Amgen BD does rightfully suck, but Amgen reps could sell HIV drugs to dying AIDS patients.